AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment

被引:12
|
作者
Prasad, Kailash [1 ]
机构
[1] Univ Saskatchewan, Coll Med, Dept Anat Physiol & Pharmacol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada
关键词
advanced glycation end products; cell receptor for age; soluble RAGE; atrial fibrillation; atrial structural remodeling; atrial electrical remodeling; treatment modalities; GLYCATION-END-PRODUCTS; CELL-ADHESION MOLECULE-1; ENDOGENOUS SECRETORY RAGE; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; SOLUBLE RECEPTOR; HYDROGEN-PEROXIDE; CARDIAC-SURGERY; NADPH OXIDASE; RISK-FACTORS;
D O I
10.1055/s-0039-3400541
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Atrial fibrillation (AF) is the most common of cardiac arrhythmias. Mechanisms such as atrial structural remodeling and electrical remodeling have been implicated in the pathogenesis of AF. The data to date suggest that advanced glycation end products (AGEs) and its cell receptor RAGE (receptor for AGE) and soluble receptor (sRAGE) are involved in the pathogenesis of AF. This review focuses on the role of AGE-RAGE axis in the pathogenesis of AF. Interaction of AGE with RAGE generates reactive oxygen species, cytokines, and vascular cell adhesion molecules. sRAGE is a cytoprotective agent. The data show that serum levels of AGE and sRAGE, and expression of RAGE, are elevated in AF patients. Elevated levels of sRAGE did not protect the development of AF. This might be due to greater elevation of AGE than sRAGE. Measurement of AGE-RAGE stress (AGE/sRAGE) would be appropriate as compared with measurement of AGE or RAGE or sRAGE alone in AF patients. AGE and its interaction with RAGE can induce AF through alteration in cellular protein and extracellular matrix. AGE and its interaction with RAGE induce atrial structural and electrical remodeling. The treatment strategy should be directed toward reduction in AGE levels, suppression of RAGE expression, blocking of binding of AGE to RAGE, and elevation of sRAGE and antioxidants. In conclusion, AGE-RAGE axis is involved in the development of AF through atrial structural and electrical remodeling. The treatment modalities for AF should include lowering of AGE, suppression of RAGE, elevation of sRAGE, and use of antioxidants.
引用
收藏
页码:72 / 80
页数:9
相关论文
共 50 条
  • [1] AGE-RAGE Stress in the Pathophysiology of Pulmonary Hypertension and its Treatment
    Prasad, Kailash
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2019, 28 (02) : 71 - 79
  • [2] The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD
    Reynaert, Niki L.
    Vanfleteren, Lowie E. G. W.
    Perkins, Timothy N.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
  • [3] AGE-RAGE Axis in the Pathophysiology of Chronic Lower Limb Ischemia and a Novel Strategy for Its Treatment
    Prasad, Kailash
    Bhanumathy, Kalpana K.
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (03) : 156 - 167
  • [4] Aftermath of AGE-RAGE Cascade in the pathophysiology of cardiovascular ailments
    Wasim, Rufaida
    Mahmood, Tarique
    Siddiqui, Mohd Haris
    Ahsan, Farogh
    Shamim, Arshiya
    Singh, Aditya
    Shariq, Mohammad
    Parveen, Saba
    LIFE SCIENCES, 2022, 307
  • [5] AGE-RAGE STRESS IN CARDIAC DISEASES
    Prasad, K.
    CARDIOLOGY, 2018, 140 : 72 - 72
  • [6] AGE-RAGE Stress and Coronary Artery Disease
    Prasad, Kailash
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2021, 30 (01) : 4 - 14
  • [7] AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease
    Prasad, Kailash
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2019, 459 (1-2) : 95 - 112
  • [8] AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease
    Prasad, Kailash
    Mishra, Manish
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2018, 27 (01) : 1 - 12
  • [9] AGE-RAGE: A hypothesis or a mechanism? [AGE-RAGE: Eine hypothese oder ein mechanismus?]
    Isermann B.
    Bierhaus A.
    Humpert P.M.
    Rudofsky G.
    Chavakis T.
    Ritzel R.
    Wendt T.
    Morcos M.
    Kasperk C.
    Hamann A.
    Nawroth P.P.
    Herz, 2004, 29 (5) : 504 - 509
  • [10] AGE-RAGE system and carcinogenesis
    Abe, Riichiro
    Yamagishi, Sho-ichi
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 940 - 945